Bonnie Gillis

Articles

Amrubicin May Be Better Than Topotecan for Second-Line Therapy of Small Cell Lung Cancer

July 28th 2011

Amrubicin improved response rates, improved progression- free survival (PFS), and achieved enhanced symptom control with acceptable toxicity compared with topotecan.

Iniparib Fails to Improve Survival as Part of Chemotherapy in Triple-Negative Breast Cancer

July 21st 2011

The addition of the PARP inhibitor iniparib failed to improve OS or PFS when added to gemcitabine/carboplatin (GC) compared with GC alone in patients with metastatic TNBC.

Novel Agent Motesanib Does Not Pan Out in Advanced NSCLC

July 20th 2011

Although once considered a promising drug for lung cancer and other tumor types, motesanib added to carboplatin/paclitaxel chemotherapy did not improve overall survival.

Translational Science in Prostate Cancer: Exploring the Synergies Between Basic Research and Clinical Medicine

April 21st 2011

Translational medicine is currently the focus of much attention in the medical and research community and is the wave of the foreseeable future

Imaging for Prostate Cancer Does Not Adhere to National Guidelines

March 23rd 2011

According to a retrospective review of a SEER-Medicare database presented at the ASCO Genitourinary Cancers Symposium

Robotic-Assisted Laparoscopic Radical Prostatectomy Has Steep Learning Curve

March 23rd 2011

Performing robotic-assisted laparoscopic radical prostatectomy (RALP) surgeries at an expert level is not as easy as has been previously assumed

Bicalutamide During and After Radiation Improves Progression-Free Survival in Men With Rising PSA Following Primary Surgery for Prostate Cancer

March 23rd 2011

According to primary results of a phase III randomized, placebocontrolled trial reported at the 2011 ASCO Genitourinary Cancers Symposium

Insured Women Are Skipping Mammograms at High Rates

March 22nd 2011

About 40% of insured women in the United States are not undergoing screening mammography at least every 2 years in keeping with guidelines from the USPSTF.

Dutasteride Followed By Watchful Waiting May Delay Cancer Progression in Men With Early Prostate Cancer

March 22nd 2011

Dutasteride, a drug commonly used to treat benign prostatic hyperplasia, may also be useful as part of a "watchful waiting" strategy

Study Presents Preliminary But Impressive Data In Metastatic Castration- Resistant Prostate Cancer

March 21st 2011

cabozantinib (XL184) - a novel wide-spectrum tyrosine kinase inhibitor (TKI) - achieved dramatic results in patients with castration-resistant prostate cancer

Exercise, Weight-Lifting Help in Preventing Lymphedema

March 15th 2011

Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

ASH 2010: Large International Study Backs Use of Imatinib in Adults With Ph ALL

March 10th 2011

Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia

ASH 2010: A New Scoring System Assesses the Risk of Recurrent Venous Thromboembolism

March 10th 2011

A new scoring system has been developed that is designed to predict the risk of recurrent venous thromboembolism (VTE) in a patient with cancer.

ASH 2010: Ponatinib Inhibits Mutations That Block Treatment Paths for CML, ALL, and AML

March 10th 2011

An investigational pan-BCR-ABL inhibitor designed to inhibit the entire spectrum of mutations responsible for resistance to drugs such as imatinib (Gleevec) and its cousins nilotinib (Tasigna) and dasatinib (Sprycel) appears to fulfill its promise.

ASH 2010: Intensified R-ACVBP More Effective and More Toxic Than R-CHOP in Diffuse Large B-Cell Lymphoma

March 9th 2011

Intensified immunochemotherapy with R-ACVBP significantly improved event-free survival, progression-free survival, disease-free survival, and overall survival compared with R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL), but at the cost of increased hematologic toxicity.

ASH 2010: Carfilzomib Shrinks Tumors in More Than One-Third of Pretreated Myeloma Patients

March 9th 2011

Carfilzomib, described as a next-generation protease inhibitor, produced durable responses in patients with multiple myeloma whose disease relapsed after or proved refractory to all available therapies.

ASH 2010: Brentuximab Vedotin Produces High Response Rate in Relapsed or Refractory Hodgkin Lymphoma

March 9th 2011

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a pivotal phase II study involving younger patients with relapsed or refractory Hodgkin lymphoma.

ASH 2010: Bosutinib Shows Promise as First-line Treatment of Chronic Myelogenous Leukemia

March 9th 2011

Bosutinib (SKI-606) seems poised to join the tyrosine kinase inhibitors (TKIs) imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna) as a first-line therapy option for patients with chronic myelogenous leukemia in the chronic phase.

ASH 2010: Brentuximab Showing Promise as Hodgkin Lymphoma Therapy

March 8th 2011

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a phase II study of younger patients with relapsed or refractory Hodgkin lymphoma (HL) who had no other treatment options

SABCS Coverage: Adding Everolimus to Tamoxifen Improves Outcomes in Metastatic Breast Cancer

March 2nd 2011

Everolimus (Afinitor) added to tamoxifen delayed tumor progression in patients with hormone receptor (HR)-positive, HER2-negative, advanced metastatic breast cancer